Quantifying The Economic Burden Of Inadequate Symptom Control Among Patients With IBS-D

1 mins read

As the industry shifts from volume to value based models, it is becoming necessary for Pharmaceutical companies to demonstrate the value their brands deliver through outcomes and evidence based studies. One example of such study is economic burden of inadequate symptom control.

Axtria recently collaborated on a study to analyze the "Economic burden of inadequate symptom control among US commercially insured patients with irritable bowel syndrome with diarrhea".

We are very proud to share that the manuscript of the study has been published in the Journal of Medical Economics (JME 2017). The abstract of the manuscript can be found online here

The economic burden associated with inadequate symptom control among patients with irritable bowel syndrome with diarrhea (IBS-D) is not well understood.

The objective of the study was to identify patients with indicator of inadequate symptom control and to evaluate total annual all-cause health care resource use and costs among IBS-D patients with and without evidence of inadequate symptom control in a U.S. commercially insured population. The aim was also to estimate incremental all-cause health care costs of IBS-D patients with versus without evidence of inadequate symptom control.

The study concluded that inadequate symptom control is highly prevalent among patients being treated for IBS-D and is associated with a substantial economic burden. There exists a significant unmet need for more effective therapeutic options to treat and manage the multiple symptoms of IBS-D. Treating IBS-D patients effectively early in the management of their condition could potentially reduce healthcare resource use and costs associated with continued healthcare-seeking behavior among those treated inadequately with initial therapies.

To read the full manuscript subscribe to or write to, if you are interested talking directly to our experts involved in this study. We would be happy to setup a meeting. 

For Questions, Contact Us Now

Recommended Blogs

This blog is the ­second of a two-part series. It highlights three of the six reasons for emerging pharma companies to move away from siloed point-solutions and choose an integrated end-to-end ...

5 mins read

The commercial ecosystem of the medical device industry is an intricate one. Medical device sales teams constantly watch out for opportunities across the sales process, beyond the overarching life ...

6 mins read

Rid your binge-watching boredom through artificial intelligence and machine learning – a leading cause of the pharmaceutical industry's best innovations and advancements. As the projected weeks in ...

4 mins read

Let Us Show You What Axtria’s 

Solutions Can Do For You